Reuters Pharma EU: Day 1 Highlights and Key Takeaways
The pharmaceutical industry achieved record milestones in 2024 with 105 new active substances approved globally, while a widening gap between FDA approval and payer coverage is reshaping market access strategy for European pharma companies.
Key Takeaways
- Reuters Events: Pharma EU conference details remain unavailable — no confirmed 2024 event date, venue, or speaker roster could be verified from authoritative sources.
- Pharmaceutical industry achieved record milestones in 2024 — 105 new active substances approved globally, with the U.S. pharmaceutical market reaching USD 458.9 billion.
- FDA-to-payer coverage gap widened significantly — specialty drugs, orphan therapies, and cell/gene treatments now face extended restrictions beyond FDA-approved labels, reshaping market access strategy.
- Precision medicine and genomics adoption accelerated — advanced genomic equipment adoption increased 36%, with biologics and biosimilars representing 32% of new drug approvals.
Editorial Note: Event Verification Required
NovaPharmaNews conducted extensive research to verify details of the Reuters Events: Pharma EU 2024 conference referenced in this article plan. No confirmed event date, venue, speaker roster, or registration information could be located through official Reuters Events channels or industry databases. The following analysis therefore focuses on pharmaceutical industry trends and developments most relevant to European pharma stakeholders during 2024, rather than specific conference session highlights.
Readers seeking information about Reuters Events pharma conferences are encouraged to visit the official Reuters Events website directly for current event schedules and registration details.
Pharmaceutical Industry Context: 2024 Landscape
The global pharmaceutical industry entered 2024 amid transformative shifts in drug development, regulatory approval, and market access. Understanding these trends provides essential context for industry professionals attending major pharma conferences across Europe and beyond.
Record Drug Approvals and Pipeline Expansion
The pharmaceutical sector achieved a historic milestone in 2024: 105 new active substances received regulatory approval globally, surpassing the previous record of 97 approvals in 2021. In the United States specifically, 61 novel drugs were approved, with more than three-quarters classified as specialty, rare disease, or cell and gene therapy products.
This concentration of complex, high-cost therapies continued into early 2025, where 72% of 58 novel drug approvals fell within these same therapeutic archetypes. The overall pharmaceutical pipeline expanded to a record 22,825 pipeline drugs, with Pfizer leading the field with 32 new candidates in development.
Market Valuation and Revenue Shifts
The U.S. pharmaceutical market reached USD 458.9 billion in 2024 and is projected to grow to USD 1.2 trillion by 2033, reflecting sustained industry expansion despite regulatory and payer pressures. A significant market realignment occurred when Eli Lilly increased sales from USD 45 billion in 2024 to USD 65.2 billion, surpassing Bristol Myers Squibb, Novartis, and AstraZeneca to become a leading pharmaceutical company by revenue.
Emerging Trends Reshaping European Pharma Strategy
Widening FDA-to-Payer Coverage Gap
A critical trend emerged in 2024 that directly impacts market access strategy across Europe and North America: the gap between FDA approval and payer coverage widened significantly. The majority of higher-cost drugs—including specialty products, orphan therapies, and cell and gene treatments—now face restrictions that extend beyond their FDA-approved labels.
Five years prior, such label restrictions were reserved for select products; today they represent a consistent feature across therapeutic areas and product archetypes. This shift has profound implications for European pharmaceutical companies navigating both U.S. market entry and European Health Technology Assessment (HTA) requirements.
Intensified Utilization Management Across Payers
Payers increasingly deployed traditional management tools including prior authorization, step therapy, formulary positioning, and mandatory specialist involvement. Notably, payers began managing high-cost medical benefit drugs using tools historically associated with pharmacy benefits, with intensified scrutiny of buy-and-bill reimbursement models.
Oncology became a model for institutionalized management frameworks, while immunology and competitive biologic markets saw payers demanding clear head-to-head evidence to justify differential treatment. This trend underscores the importance of robust health economic data and real-world evidence in securing favorable coverage decisions.
Precision Medicine and Genomics Acceleration
Advanced genomic equipment adoption increased by 36% in 2024, supporting precision medicine initiatives across research and clinical settings. Biologics and biosimilars accounted for 32% of new drug approvals, reflecting the industry's strategic shift toward complex therapeutic mechanisms.
The industry moved away from traditional development paths toward more sophisticated therapeutic strategies, reflecting commitment to addressing unmet medical needs through diverse drug types, from small molecules to advanced biotech innovations. This trend is particularly relevant for European biotech companies competing in precision oncology, immunology, and rare disease segments.
Implications for European Pharmaceutical Stakeholders
These 2024 industry developments carry significant implications for European pharmaceutical companies, regulatory bodies, and healthcare systems:
- Regulatory Strategy: The record approval numbers suggest continued FDA receptiveness to novel mechanisms, but European companies must prepare for more stringent HTA scrutiny and payer negotiations, particularly for specialty and high-cost therapies.
- Market Access Planning: The widening FDA-to-coverage gap necessitates earlier health economic modeling and real-world evidence generation during clinical development phases.
- Competitive Positioning: Eli Lilly's revenue surge reflects successful execution in high-value therapeutic areas. European competitors must differentiate through precision medicine capabilities, robust clinical evidence, and demonstrated health economic value.
- Biosimilar Strategy: With biologics representing one-third of new approvals, European companies should evaluate biosimilar development opportunities, particularly in maturing biologic markets where cost-effectiveness arguments strengthen market access.
What to Watch Next
Industry professionals should monitor several key developments in the coming months:
- European Medicines Agency (EMA) approval trends: Watch for alignment or divergence between EMA and FDA approval decisions, particularly in specialty and rare disease segments.
- HTA framework evolution: European health technology assessment bodies continue refining methodologies for complex therapies, cell/gene treatments, and precision medicine products.
- Payer coverage policies: Monitor how European payers respond to the widening FDA-to-coverage gap, particularly regarding orphan drugs and advanced therapies.
- Biosimilar market dynamics: Track biosimilar adoption rates and pricing pressures as additional reference biologics lose exclusivity.
- Precision medicine infrastructure: Observe investments in genomic sequencing, companion diagnostics, and real-world data platforms across European healthcare systems.
Frequently Asked Questions
Q: Where can I find information about Reuters Events pharma conferences?
A: Reuters Events maintains a comprehensive events calendar at reuters.com/events. Specific pharma-focused events, including European editions, are listed with dates, venues, speaker information, and registration details. For inquiries about specific 2024 or 2025 events, contact Reuters Events directly through their website.
Q: What drove the record number of drug approvals in 2024?
A: The 105 new active substances approved in 2024 reflect sustained pharmaceutical innovation, particularly in specialty therapeutics, rare diseases, and advanced modalities (cell and gene therapies). Regulatory agencies, including the FDA and EMA, maintained efficient review timelines while maintaining rigorous safety and efficacy standards. The concentration of complex therapies suggests industry focus on addressing previously unmet medical needs in high-value therapeutic areas.
Q: How does the FDA-to-payer coverage gap affect drug commercialization?
A: The widening gap between FDA approval and payer coverage means that even FDA-approved drugs may face significant restrictions—such as prior authorization, step therapy, or limited formulary placement—that extend beyond the approved indication. This requires pharmaceutical companies to develop robust health economic data, conduct real-world evidence studies, and engage payers early in development to secure favorable coverage decisions. The gap particularly impacts specialty drugs, orphan therapies, and high-cost treatments.
Q: Why is precision medicine adoption accelerating in pharma?
A: Precision medicine adoption is driven by multiple factors: (1) declining genomic sequencing costs and increased accessibility, (2) regulatory incentives for companion diagnostics and biomarker-driven development, (3) payer demand for evidence-based patient stratification, and (4) clinical benefits demonstrated in oncology and immunology. The 36% increase in advanced genomic equipment adoption reflects industry-wide commitment to developing targeted therapies that improve efficacy while reducing adverse events and healthcare costs.
Q: What should European pharma companies prioritize in 2025?
A: European pharmaceutical companies should prioritize: (1) robust health economic evidence generation aligned with European HTA requirements, (2) precision medicine and companion diagnostic development, (3) real-world evidence collection to support payer negotiations, (4) biosimilar development opportunities in maturing biologic markets, and (5) early engagement with European regulatory and payer stakeholders to align development strategies with market access requirements. Additionally, monitoring EMA-FDA regulatory alignment and European HTA framework evolution remains critical for competitive positioning.
References
- Clinical Leader. (2024). "Pharma R&D Annual Review Supplement: New Active Substances." Retrieved from clinicalleader.com
- IntegriChain. (2024). "The Launch Lens: Trends in Payer Management Across Archetypes for New Market Entrants." Retrieved from integrichain.com
- OpenPR. (2024). "U.S. Pharmaceutical Market Size Projected to Reach USD 1.2 Trillion by 2033." Retrieved from openpr.com
- Reuters Events. Official Events Calendar. Retrieved from reuters.com/events
- U.S. Food and Drug Administration. (2024). Drug Approvals and Databases. Retrieved from fda.gov/drugs
- European Medicines Agency. (2024). EMA Approvals and Regulatory Guidance. Retrieved from ema.europa.eu
NovaPharmaNews is committed to fact-based pharmaceutical journalism. This article was prepared based on available industry data and research. Readers are encouraged to verify event details directly with Reuters Events and consult official regulatory sources for the most current information.
